Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYTĀ® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Analyst coverage

Analyst coverage

Firm Analyst
Barclays
Peter Lawson, D. Phil.
Citi
David Lebowitz
Cowen and Company
Marc Frahm, Ph.D.
Goldman, Sachs & Co.
Salveen Richter
Guggenheim Securities
Michael Schmidt, Ph.D.
H.C. Wainwright
Andrew Fein
JMP Securities
Reni Benjamin, Ph.D.
Leerink
Andrew Berens, M.D.
Morgan Stanley
Michael Ulz
Needham & Company
Ami Fadia
Oppenheimer & Co.
Matthew Biegler
Piper Sandler
Chris Raymond
Raymond James
Laura Prendergast, Ph.D.
Robert W. Baird
Colleen M. Kusy
Stephens & Co.
Sudan Loganathan Ph.D.
Stifel
Brad Canino
Wedbush PacGrow Life Sciences
David Nierengarten, Ph.D.
Wells Fargo Securities
Derek Archila
Blueprint Medicines Corporation is followed by the analysts listed on this page. Please note that any opinions, estimates or forecasts regarding Blueprint Medicines Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Blueprint Medicines Corporation or its management. Blueprint Medicines Corporation does not by its reference here or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.